Literature DB >> 7350242

The interaction of heparin with plasma proteins. Demonstration of different binding sites for antithrombin III complexes and antithrombin III.

E J McKay, C B Laurell.   

Abstract

Affinity chromatography of plasma and serum with the use of heparin conjugated Sepharose has confirmed the existence of two types of protein binding sites. A minor heparin fraction binds free AT III selectively and firmly but not its protease complexes. The complexes bind less firmly to another, much larger heparin fraction together with a select group of the plasma proteins at physiological pH and ionic strength. These included complement proteins (C1q, C2, factor B, properdin, and beta 1H), protease inhibitors (inter-alpha-trypsin inhibitor and C3b inactivator) and cell surface proteins (protein HC and fibronectin) as well as beta-lipoproteins. The results demonstrate that affinity chromatography with heparin-Sepharose is extremely useful as an early preparative step in the isolation of these minor plasma components. The results also indicate that the said proteins can be linked to cell surfaces carrying heparinoids in the intercellular space.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7350242

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  5 in total

1.  The major fimbrial subunit of Bordetella pertussis binds to sulfated sugars.

Authors:  C A Geuijen; R J Willems; F R Mooi
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Binding of transferrin to the core protein of fibroblast proteoheparan sulfate.

Authors:  L A Fransson; I Carlstedt; L Cöster; A Malmström
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

3.  Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen.

Authors:  H Lilja; J Oldbring; G Rannevik; C B Laurell
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

4.  Novel polysaccharide-decorated poly(isobutyl cyanoacrylate) nanoparticles.

Authors:  Cédric Chauvierre; Denis Labarre; Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

5.  Antithrombin III (AT III) Padua2: a "new" congenital abnormality with defective heparin co-factor activities but no thrombotic disease.

Authors:  A Girolami; F Fabris; G Cappellato; L Sainati; G Boeri
Journal:  Blut       Date:  1983-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.